Gene construct comprising nucleotides encoding decoy peptides for inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban and nucleotides encoding CCN5 protein or fragments thereof, and use thereof
The use of a decoy peptide and CCN5 protein gene construct addresses the limitations of current heart failure treatments by inhibiting PP1-mediated dephosphorylation and promoting tissue repair, showing promise in improving heart function and reducing fibrosis in heart failure models.
Patent Information
- Application Number
- PCT/KR2024/007650
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-05
- Filing Date
- 2024-06-04
- Publication Date
- 2024-12-12
AI Technical Summary
Current treatments for heart failure, particularly those targeting single drug mechanisms or disease pathways, are insufficient in addressing the complex pathological remodeling and fibrosis that contribute to heart disease progression, leading to high mortality rates and significant treatment costs.
A nucleotide encoding a decoy peptide that inhibits protein phosphatase 1 (PP1)-mediated dephosphorylation of phospholamban (PLB) and a gene construct encoding the CCN5 protein or its fragment, which are used to create a recombinant vector or virus for therapeutic delivery, aiming to restore heart function by inhibiting PP1-mediated dephosphorylation and promoting cellular communication and tissue repair.
The simultaneous expression of decoy peptide and CCN5 protein demonstrates synergistic therapeutic effects in mouse models of heart failure, improving cardiac contractility, reducing fibrosis, and enhancing heart function, offering a novel approach to treating heart disease by targeting multiple disease mechanisms.
Smart Images

Figure KR2024007650_12122024_PF_FP_ABST
Abstract
Description
Gene construct comprising a nucleotide encoding a decoy peptide for inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban and a nucleotide encoding a CCN5 protein or a fragment thereof, and uses thereof
[0001] The present invention relates to a pharmaceutical composition for the prevention and treatment of heart disease. Specifically, the present invention relates to a gene construct comprising a nucleotide encoding a decoy peptide that inhibits protein phosphatase 1 (PP1)-mediated dephosphorylation of phospholamban (PLB); and a nucleotide encoding the CCN5 protein or a fragment thereof, and a pharmaceutical composition for the prevention or treatment of heart disease comprising the same as an active ingredient.
[0002] Heart failure (HF) is a complex disease characterized by structural and functional impairment of the ventricle's pumping function, which fills and ejects blood. Heart failure has a mortality rate of over 50% within five years of diagnosis, making it a higher mortality rate than cancer. The number of heart failure patients worldwide is estimated to be approximately 38 million, and the prevalence is increasing with the aging population. However, there is no fundamental cure for heart failure; treatment can only slow the progression of the disease. Consequently, medical management incurs significant costs, placing a significant burden on patients (Braunwald E., Lancet, 385(9970):812-824, 2015).
[0003] Heart failure is caused by cardiac conditions, genetic defects, and systemic diseases. Representative diseases associated with its onset include ischemic, hypertensive, and valvular heart diseases. Furthermore, it can be caused by primary cardiomyopathy of genetic or acquired origin, secondary cardiomyopathy including amyloidosis, congenital heart disease, and pericardial disease (Maron BJ et al., Circulation, 113(14):1807-1816, 2006). Heart failure caused by various heart diseases results in pathological cardiac remodeling, which manifests as structural and functional abnormalities of the heart. Specifically, cellular remodeling occurs due to changes in the size, shape, and function of cardiomyocytes, while tissue remodeling occurs due to excessive accumulation of extracellular matrix (ECM), leading to fibrosis of cardiac tissue. This pathological cardiac remodeling involves pathological changes in the transcriptional, signaling, structural, electrophysiological, and functional roles of cardiomyocytes.
[0004] The extracellular matrix of cardiac muscle is a sophisticated structure that supports the mechanical functions of efficient contraction and relaxation of cardiac muscle cells, and plays a role in promoting appropriate force transmission, electrical signal transmission, intercellular communication, and exchange of metabolites within the microenvironment of cardiac muscle. Increased stress, damage, and disease of the cardiac wall promote fibrosis in the extracellular matrix, thereby impairing the motor functions of cardiomyocytes and myofibrils, including contraction and relaxation (Li AH. et al., Circ Res., 114(5):916-927, 2014).
[0005] Furthermore, pathological remodeling leads to dysfunction in cardiac muscle contraction and relaxation, as well as cardiomyocyte death. At the cellular level, cardiomyocyte hypertrophy and death affect myocardial excitation-contraction coupling (EC), leading to pathological changes in the molecular mechanisms regulating cardiomyocyte contraction, cell survival, mitochondrial function related to energy metabolism, and oxidative stress.
[0006] In cardiac tissue, pathological structural changes occur, including the generation and fibrosis of myofibroblasts, stiffening of vascular smooth muscle, dysfunction of vascular endothelial cells, and the promotion of immune cell inflammation. This cellular disease progression leads to tissue-level remodeling through an integrated process that includes cardiomyocyte hypertrophy and death, vascular loss, fibrosis, inflammation, metabolic dysfunction, and electrophysiological remodeling, ultimately leading to heart failure.
[0007] Neurohormonal blockers have been used to treat heart failure for over 40 years. However, despite their effectiveness in alleviating symptoms and reducing the stress on the heart, the prognosis for heart failure patients remains extremely pessimistic, with mortality rates reaching 50% after five years and 90% after ten years. Furthermore, once heart failure progresses to severe stages, the only treatment options are cardiac assist devices and heart transplantation. Therefore, the development of novel therapies that fundamentally treat heart failure and restore the heart is urgently needed.
[0008] Among the newly understood disease mechanisms in the field of heart failure treatment development, it has been revealed that cardiac remodeling, including fibrosis, which directly affects cardiac pumping function, and cardiomyocyte damage interact to form a vicious cycle that is closely linked to the development, progression, and prognosis of the disease.
[0009] Therefore, since treatment of a single drug target or disease mechanism may result in insufficient results in the treatment of heart disease, research on combination therapies that treat novel cellular-level functional restoration and cardiac histological remodeling is needed.
[0010] Accordingly, the present inventors conducted research to develop an effective treatment for heart disease, and as a result, they confirmed that a genetic construct, a recombinant vector, and a recombinant virus including a nucleotide encoding a decoy peptide that inhibits protein phosphatase 1 (PP1)-mediated dephosphorylation of phospholamban (PLB) and a nucleotide encoding a CCN5 protein or a fragment thereof exhibited a synergistic therapeutic effect on heart disease in a mouse model in which heart failure was induced by various etiologies, thereby completing the present invention.
[0011] One aspect of the present invention provides a gene construct comprising a nucleotide encoding a decoy peptide that inhibits protein phosphatase 1 (PP1)-mediated dephosphorylation of phospholamban (PLB); and a nucleotide encoding a CCN5 protein or a fragment thereof.
[0012] Another aspect of the present invention provides a recombinant vector comprising the genetic construct.
[0013] Another aspect of the present invention provides a recombinant virus comprising the genetic construct.
[0014] Another aspect of the present invention provides a pharmaceutical composition comprising the genetic construct, the recombinant vector or the recombinant virus as an active ingredient.
[0015] Another aspect of the present invention provides a method for preventing or treating heart disease, comprising administering the pharmaceutical composition to a subject.
[0016] Another aspect of the present invention provides a method for preventing or treating heart disease, comprising administering to a subject a recombinant vector loaded with a nucleotide encoding a decoy peptide that inhibits protein phosphatase 1 (PP1)-mediated dephosphorylation of phospholamban (PLB), or a recombinant virus comprising the same; and administering to a subject a recombinant vector loaded with a nucleotide encoding a CCN5 protein or a fragment thereof, or a recombinant virus comprising the same.
[0017] Another aspect of the present invention provides a use of the pharmaceutical composition for preventing or treating heart disease.
[0018] Another aspect of the present invention provides a use of the pharmaceutical composition for preparing a medicament for the prevention or treatment of heart disease.
[0019] The present invention relates to a genetic construct comprising a nucleotide encoding a decoy peptide that inhibits protein phosphatase 1 (PP1)-mediated dephosphorylation of phospholamban (PLB); and a nucleotide encoding a CCN5 protein or a fragment thereof, and a pharmaceutical composition comprising the same. The pharmaceutical composition of the present invention exhibits a synergistic therapeutic effect by simultaneously expressing the decoy peptide that inhibits PP1-mediated dephosphorylation and the CCN5 protein, thereby being remarkably effective in preventing or treating heart disease.
[0020] Figure 1a is a diagram showing the structure of the pUC-scCMV-SPTATm3-SE-P2A-CCN5 vector.
[0021] Figure 1b is a diagram showing the structure of the pUC-scCMV-SPTATm3-SESE-P2A-CCN5 vector.
[0022] Figure 1c is a diagram showing the structure of the pUC-scCMV-SPTATm3-SESESE-P2A-CCN5 vector.
[0023] Figure 1d is a diagram showing the structure of the pUC-scCMV-SPTATm3-SESESE-dNP2-SESESE-CCN5 vector.
[0024] Figure 2 is a drawing showing the expression of the decoy peptide and CCN5 protein in cells by the vector of the present invention, in which the protein was confirmed in a lysate. CCN5 refers to a CCN5-only construct, SE-CCN5 refers to a CCN5 multiple expression construct using a SE peptide sequence (decoy peptide sequence) without CPP and P2A, SPTATm3-SE-CCN5 refers to a CCN5 multiple expression construct using a SE peptide using SPTATm3 as a CPP and P2A, and dNP2-SE-CCN5 refers to a CCN5 multiple expression construct using a SE peptide using dNP2 as a CPP and P2A.
[0025] Figure 3 is a drawing showing the protein confirmed in the media to confirm whether the decoy peptide and CCN5 protein of the present invention are secreted outside the cell. CCN5 refers to a CCN5 single construct, SE-CCN5 refers to a CCN5 multiple expression construct using a SE peptide sequence (decoy peptide sequence) without CPP and P2A, SPTATm3-SE-CCN5 refers to a CCN5 multiple expression construct using a SE peptide using SPTATm3 as a CPP and P2A, and dNP2-SE-CCN5 refers to a CCN5 multiple expression construct using a SE peptide using dNP2 as a CPP and P2A.
[0026] Figure 4 is an image confirming whether the expression level of CCN5 protein increases according to the repetition of nucleotides encoding decoy peptides. SPTATm3-SE-CCN5 is a CCN5 multiple expression construct using SE peptide sequence (decoy peptide sequence) and P2A, SPTATm3-SESE-CCN5 is a CCN5 multiple expression construct using P2A and a peptide sequence in which the SE peptide sequence is repeated twice, SPTATm3-SESESE-CCN5 is a CCN5 multiple expression construct using P2A and a peptide sequence in which the SE peptide sequence is repeated three times, and SPTATm3-dNP2SE-CCN5 is a CCN5 multiple expression construct using P2A and a peptide sequence in which the SE peptide sequence is repeated three times, using SPTATm3 and dNP2 as CPPs.
[0027] Figure 5 is an image confirming the degree to which the decoy peptide and CCN5 protein were introduced into smooth muscle cells (SMCs) according to the repetition of the nucleotide encoding the decoy peptide (p value: **<0.005, *<0.05, ns>0.05). SE-CCN5 is a CCN5 multiple expression construct using the SE peptide sequence and P2A, SESE-CCN5 is a CCN5 multiple expression construct using the peptide sequence with two repetitions of the SE sequence and P2A, SESESE-CCN5 is a CCN5 multiple expression construct using the peptide sequence with three repetitions of the SE sequence and P2A, and CCN5 is a CCN5 single construct.
[0028] Figure 6 is an image confirming the degree to which the decoy peptide and CCN5 protein were introduced into endothelial cells (ECs) according to the repetition of the nucleotide encoding the decoy peptide (p value: **<0.005, *<0.05, ns>0.05). SE-CCN5 is a CCN5 multiple expression construct using the SE peptide sequence and P2A, SESE-CCN5 is a CCN5 multiple expression construct using the peptide sequence with two repetitions of the SE sequence and P2A, SESESE-CCN5 is a CCN5 multiple expression construct using the peptide sequence with three repetitions of the SE sequence and P2A, and CCN5 is a CCN5 single construct.
[0029] Figure 7 is an image showing the protein expression levels of a-SMA, p21, and GAPDH according to the repetition of nucleotides encoding the decoy peptide after treatment of normal human ventricular cardiac fibroblasts (NHCF-v) with TGF beta and then treatment with decoy peptide and CCN5 protein (p value: **<0.005, *<0.05, ns>0.05). SE-CCN5 is a CCN5 multiple expression construct using the SE peptide sequence and P2A, SESE-CCN5 is a CCN5 multiple expression construct using the peptide sequence with two repetitions of the SE sequence and P2A, SESESE-CCN5 is a CCN5 multiple expression construct using the peptide sequence with three repetitions of the SE sequence and P2A, and CCN5 is a CCN5 single construct.
[0030] Figure 8 is a graph showing the mRNA expression of a-SMA confirmed through qRT-PCR in the experimental group treated with a medium containing decoy peptide and CCN5 protein in NHCF-v (p value: **<0.005, *<0.05, ns>0.05). SE-CCN5 is a CCN5 multiple expression construct using the SE peptide sequence and P2A, SESE-CCN5 is a CCN5 multiple expression construct using the peptide sequence with two repetitions of the SE sequence and P2A, SESESE-CCN5 is a CCN5 multiple expression construct using the peptide sequence with three repetitions of the SE sequence and P2A, and CCN5 is a CCN5 single construct.
[0031] Figure 9 is a graph showing the mRNA expression of Vimentin confirmed through qRT-PCR in the experimental group treated with a medium containing decoy peptide and CCN5 protein in NHCF-v (p value: **<0.005, *<0.05, ns>0.05). SE-CCN5 is a CCN5 multiple expression construct using the SE peptide sequence and P2A, SESE-CCN5 is a CCN5 multiple expression construct using the peptide sequence with two repetitions of the SE sequence and P2A, SESESE-CCN5 is a CCN5 multiple expression construct using the peptide sequence with three repetitions of the SE sequence and P2A, and CCN5 is a CCN5 single construct.
[0032] Figure 10 is a graph showing the mRNA expression of Fibronectin in the experimental group treated with a medium containing decoy peptide and CCN5 protein in NHCF-v, confirmed through qRT-PCR (p value: **<0.005, *<0.05, ns>0.05). SE-CCN5 is a CCN5 multiple expression construct using the SE peptide sequence and P2A, SESE-CCN5 is a CCN5 multiple expression construct using the peptide sequence with two repetitions of the SE sequence and P2A, SESESE-CCN5 is a CCN5 multiple expression construct using the peptide sequence with three repetitions of the SE sequence and P2A, and CCN5 is a CCN5 single construct.
[0033] Figure 11a is a schematic diagram showing the structure of construct BTG011, which simultaneously expresses the SPTATm3-SESE peptide and the CCN5 protein through the CMV promoter.
[0034] Figure 11b is a drawing showing the protein confirmed in the lysate to confirm whether the decoy peptide and CCN5 protein are expressed in cells by the vector of the present invention. CCN5 refers to a CCN5 single construct, SP-TATm3-SESE-P2A-CCN5 refers to a CCN5 multiple expression construct using an SE peptide sequence including an N-terminal CPP and P2A, CCN5-P2A-SP-TATm3-SESE refers to a SE peptide multiple expression construct including a CPP using CCN5 and P2A, and SP-SESE-TATm3-P2A-CCN5 refers to a CCN5 multiple expression construct using an SE peptide sequence including a C-terminal CPP and P2A.
[0035] Figure 11c is a drawing showing the protein confirmed in the media to confirm whether the decoy peptide and CCN5 protein of the present invention are secreted outside the cell. CN5 is a CCN5 single construct, SP-TATm3-SESE-P2A-CCN5 is a CCN5 multiple expression construct using SE peptide sequence including N-terminal CPP and P2A, CCN5-P2A-SP-TATm3-SESE is a SE peptide multiple expression construct including CPP using CCN5 and P2A, and SP-SESE-TATm3-P2A-CCN5 is a CCN5 multiple expression construct using SE peptide sequence including C-terminal CPP and P2A.
[0036] Figure 12 is a graph showing myocardial contractility after injection of BTG001 (expressing CCN5 alone), BTG010 (expressing CPP and decoy peptide (TATm3-SESE)), and BTG011 (expressing TATm3-SESE and CCN5) AAV viruses at different doses in an AngII-induced heart failure mouse model (p value: **<0.005, n = 3-6).
[0037] Figure 13 is an image showing histological confirmation of the degree of cardiac fibrosis after injection of BTG001, BTG010, and BTG011 AAV viruses at different doses in an AngII-induced heart failure mouse model.
[0038] Figure 14 is a graph showing the degree of cardiac fibrosis quantified using an Images scope after injection of BTG001, BTG010, and BTG011 AAV viruses at different doses in an AngII-induced heart failure mouse model (p value: **<0.005, n=3-6).
[0039] Figure 15 is a graph showing the mouse heart weight / body weight ratio after injection of BTG001, BTG010, and BTG011 AAV viruses in a TAC (Transverse aortic constriction)-induced heart failure model (p value: **<0.005, *<0.05, n=4-7).
[0040] Figure 16 is a graph showing the fractional shortening of mouse heart contractility after injection of BTG001, BTG010, and BTG011 AAV viruses in a TAC-induced heart failure model (p value: **<0.005, *<0.05, n=4-7).
[0041] Figure 17 is an image showing histological confirmation of the degree of cardiac fibrosis after injection of BTG001, BTG010, and BTG011 AAV viruses at different doses in a TAC-induced heart failure model.
[0042] Figure 18 is a graph showing the quantification of the degree of cardiac fibrosis after injection of BTG001, BTG010, and BTG011 AAV viruses in a TAC-induced heart failure model (p value: *<0.05, n=3-4).
[0043] Figure 19 shows a schematic diagram of TAT and TATm3.
[0044] Novel genetic constructs
[0045] One aspect of the present invention provides a gene construct comprising a nucleotide encoding a decoy peptide that inhibits protein phosphatase 1 (PP1)-mediated dephosphorylation of phospholamban (PLB); and a nucleotide encoding a CCN5 protein or a fragment thereof.
[0046] Decoy peptide
[0047] As used herein, the term "decoy peptide" refers to a peptide having an activity of inhibiting protein phosphatase 1 (PP1)-mediated dephosphorylation of phospholamban (PLB). The decoy peptide may be referred to as an SE peptide. Specifically, the decoy peptide of the present invention, designed to mimic phosphorylated PLB, inhibits PP1-mediated dephosphorylation of PLB, significantly increases the phosphorylation level of PLB, and significantly improves left ventricular diastolic pressure by increasing contractile parameters.
[0048] The above decoy peptide may be composed of an amino acid sequence represented by the following structural formula (I):
[0049] X1-Ala-X2-X3-Ile-Glu-X4 (I)
[0050] At this time, the above X1 is 0 to 50 amino acid residues,
[0051] wherein X2 is Ser, Glu or Asp,
[0052] The above X3 is Thr or Glu,
[0053] wherein X4 is 0 to 50 amino acid residues,
[0054] If the above X3 is Thr, then X2 is not Ser.
[0055] At this time, the decoy peptide can inhibit protein phosphatase 1 (PP1)-mediated dephosphorylation of phospholamban (PLB) by competitive inhibition.
[0056] In the decoy peptide of the present invention, the "Ala-X2-X3-Ile-Glu" is essential for the action and function of the decoy peptide. The X1 and X4 residues can be variously modified. In this respect, the present invention may include any peptide or polypeptide comprising the "Ala-X2-X3-Ile-Glu" sequence as long as it maintains the function or activity as a decoy peptide for PP1.
[0057] The term "peptide" as used herein means a linear molecule formed by amino acid residues being joined to each other by peptide bonds.
[0058] As used herein, the term "polypeptide" means a polymer of identical or different amino acids joined by peptide bonds.
[0059] As used herein, the term "decoy peptide" is a peptide or polypeptide designed to contain a peptide sequence that mimics the short loop of phosphorylated PLB, which is capable of binding to PP1 in a competitive manner, thereby blocking the action of PP1.
[0060] As used herein, the term "PP1-mediated dephosphorylation" refers to dephosphorylation of PLB by PP1, wherein the PLB is derived from a human, and the NCBI Accession Number for its amino acid sequence is AAA60109.1, AAA60083.1, or AAD55950.1.
[0061] As used herein, the term "competitive inhibition" refers to inhibition of dephosphorylation by competitive binding to PP1 for formation of a decoy peptide-PP1 complex. The decoy peptide can bind to PP1 in a manner that competes with the phosphorylation site on PLB for binding to PP1.
[0062] The above decoy peptides include decoy peptides of any length as long as they inhibit PP1-mediated dephosphorylation of PLB. For example, the decoy peptides of the present invention can be 5 to 100 amino acids, 5 to 80 amino acids, 5 to 60 amino acids, 5 to 40 amino acids, 5 to 30 amino acids, 5 to 20 amino acids, 5 to 15 amino acids, 5 to 9 amino acids, or 6 to 9 amino acids in length.
[0063] The above decoy peptide is interpreted to include a functional equivalent of the decoy peptide of the present invention.
[0064] As used herein, the term "functional equivalent" means a modification of the amino acid sequence having amino acid substitutions, additions or deletions in a portion of the amino acid sequence of the decoy peptide of the present invention (e.g., modifications of amino acid residues surrounding the essential sequence Ala-X2-X3-Ile-Glu) while having similar or improved biological activity compared to the decoy peptide of the present invention. The amino acid substitutions may be conservative substitutions. Examples of such conservative substitutions that naturally occur in amino acids include aliphatic amino acids (Gly, Ala and Pro), hydrophobic amino acids (Ile, Leu and Val), aromatic amino acids (Phe, Tyr and Trp), acidic amino acids (Asp and Glu), basic amino acids (His, Lys, Arg, Gln and Asn) and sulfur-containing amino acids (Cys and Met). The amino acid deletions are located at a portion that is not directly related to the activity of the decoy peptide of the present invention.
[0065] In one specific example, X1 of structural formula (I) of the present invention is 0 to 40, 0 to 30, 0 to 20, 0 to 13, 0 to 10, 0 to 3, or 0 to 1 amino acid residue.
[0066] In the above structural formula (I), any amino acid that is not limited to X1 may also be positioned. In one specific example of the present invention, X1 is composed of an amino acid sequence in which 0 to 50, 0 to 40, 0 to 30, 0 to 20, 0 to 13, 0 to 10, 0 to 3, or 0 to 1 amino acid residues are connected in the N-terminal direction of the 15th amino acid of the amino acid sequence of PLB.
[0067] In one specific example, the X1 is composed of 0 or 1 amino acid residue in the N-terminal direction of the 15th amino acid of the amino acid sequence of PLB (SEQ ID NO: 27).
[0068] In one specific example, X4 of structural formula (I) of the present invention is 0 to 50, 0 to 40, 0 to 33, 0 to 30, 0 to 20, 0 to 10 or 0 to 3 amino acid residues.
[0069] In the above structural formula (I), any amino acid that is not limited to X4 may also be positioned. In one specific example of the present invention, X4 is composed of an amino acid sequence in which 0 to 50, 0 to 40, 0 to 33, 0 to 30, 0 to 20, 0 to 10, or 0 to 3 amino acid residues are connected in the C-terminal direction of the 19th amino acid of the amino acid sequence of PLB (SEQ ID NO: 27).
[0070] In one specific example, the X4 is comprised of 0 to 3 amino acid residues in the C-terminal direction of the 19th amino acid of the amino acid sequence of PLB (SEQ ID NO: 27). In one specific example, the X4 is comprised of 0, 1, 2, or 3 amino acid residues in the C-terminal direction of the 19th amino acid of the amino acid sequence of PLB (SEQ ID NO: 27).
[0071] In one specific example, X1 is Arg.
[0072] In one specific example, X4 is Met, Met-Pro or Met-Pro-Gln.
[0073] The 16th amino acid Ser residue (Ser16) and the 17th amino acid Thr residue (Thr17) of the amino acid sequence (SEQ ID NO: 27) of the PLB of the present invention are phosphorylation sites located in the flexible loop region of PLB (amino acids 14-22 of the amino acid sequence of PLB). In structural formula (I), X2 and X3 represent the amino acid positions where Ser16 and Thr17 are located in PLB, respectively.
[0074] In the present invention, the decoy peptide of the present invention can be designed by substituting Ser16 and / or Thr17 with Glu or Asp. The decoy peptide containing Glu or Asp at X2 and / or X3 of the structural formula (I) is similar to phosphorylated PLB and competes with the phosphorylation site of PLB for binding to PP1.
[0075] In one specific example, X2 may be Glu or Asp, and X3 may be Thr or Glu. In another specific example, X2 may be Glu or Asp, and X3 may be Thr.
[0076] In one specific example, X1 may be Arg, X2 may be Glu, X3 may be Thr, X4 may be Met-Pro-Gln (SEQ ID NO: 18); X1 may be Arg, X2 may be Ser, X3 may be Glu, X4 may be Met-Pro-Gln (SEQ ID NO: 19); X1 may be Arg, X2 may be Asp, X3 may be Thr, X4 may be Met-Pro-Gln (SEQ ID NO: 20); X2 may be Glu, X3 may be Thr, X4 may be Met-Pro-Gln (SEQ ID NO: 21); X1 may be Arg, X2 may be Glu, X3 may be Thr, X4 may be Met (SEQ ID NO: 22); or X1 may be Arg, X2 may be Glu, X3 may be Thr (SEQ ID NO: 23).
[0077] In one specific example, X1 can be Arg, X2 can be Glu, X3 can be Thr, X4 can be Met-Pro; X1 can be Arg, X2 can be Asp, X3 can be Thr, X4 can be Met; X1 can be Arg, X2 can be Asp, X3 can be Glu, X4 can be Met-Pro; X1 can be Arg, X2 can be Asp, X3 can be Glu, X4 can be Met-Pro; X1 can be Arg, X2 can be Asp, X3 can be Glu, X4 can be Met-Pro-Gln; X1 can be Arg, X2 can be Glu, X3 can be Glu, X4 can be Met-Pro; or X1 can be Arg, X2 can be Glu, X3 can be Glu, X4 can be Met-Pro-Gln.
[0078] In one specific embodiment, the decoy peptide of the present invention comprises any one amino acid sequence selected from the group consisting of SEQ ID NOs: 18 to 23.
[0079] In one specific embodiment, the decoy peptide can comprise a sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% identity to the amino acid sequence of SEQ ID NOs: 18 to 23.
[0080] In one specific example, the nucleotide sequence encoding the decoy peptide may comprise the nucleotide sequence of SEQ ID NO: 7 or 9.
[0081] In one specific embodiment, the nucleotide sequence encoding the decoy peptide can comprise a sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% identity to the nucleic acid sequence of SEQ ID NO: 7 or 9.
[0082] CCN5 protein or fragment thereof
[0083] The term "CCN5 protein (cellular communication network factor 5 protein)" used herein refers to a stromal cell protein belonging to the CCN family that plays various roles in regulating cellular functions such as vascular diseases, angiogenesis, tumorigenesis, fibrotic disease induction, cell differentiation, and survival. Unlike other CCN family proteins, the CCN5 protein does not have a C-terminal domain and is also named WISP-2, HICP, Cop1, CTGF-L, etc. In addition, the CCN5 protein is composed of a single polypeptide chain with a 250 amino acid sequence. The CCN5 protein has a 22 amino acid secretion-inducing sequence at the N-terminus, so it is secreted outside the cell and functions as a signaling protein.
[0084] Specifically, the CCN5 protein may comprise an amino acid sequence of SEQ ID NO: 26. In addition, the nucleotide encoding the CCN5 protein may comprise a nucleic acid sequence of SEQ ID NO: 13.
[0085] In one specific example, the CCN5 protein may comprise an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% identity to SEQ ID NO: 26.
[0086] In one specific example, the nucleotides encoding the CCN5 protein may comprise a nucleic acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% identity to SEQ ID NO: 13.
[0087] In addition, the fragment of the CCN5 protein may be a fragment in which a portion of the N-terminus and / or C-terminus of the wild-type CCN5 is truncated, as long as the activity of the CCN5 protein is maintained. Specifically, the fragment of the CCN5 protein may be a fragment in which 1 to 30, 1 to 20, 1 to 10, or 1 to 5 amino acids are truncated from the N-terminus or C-terminus.
[0088] Gene construct structure
[0089] The term "gene construct" as used herein means a structure that enables the expression of a desired protein, etc. when recombined or introduced into a host strain or cell through transformation, and includes not only a gene encoding the desired protein, but also essential regulatory genes operably linked to enable the expression of the gene.
[0090] The genetic construct may include nucleotides encoding a decoy peptide and nucleotides encoding a CCN5 protein or a fragment thereof in a 5'- to 3'-terminal direction. Furthermore, the genetic construct may include nucleotides encoding a CCN5 protein or a fragment thereof and nucleotides encoding a decoy peptide in a 5'- to 3'-terminal direction. Furthermore, a self-cleavage sequence or IRES sequence may be included between the nucleotides encoding the decoy peptide and the nucleotides encoding the CCN5 protein or a fragment thereof.
[0091] The term "self-cleavage sequence" as used herein refers to a protein that contains both a domain having a cleavage function and a recognition sequence that the domain recognizes and cleaves, such that when certain conditions are met, the cleavage function domain is activated to recognize and cleave the recognition sequence within the same protein. Specifically, the self-cleavage sequence may be a 2A sequence.
[0092] As used herein, the term "2A self-cleaving peptides" refers to self-cleaving sequences found in a wide variety of viral families, sharing the core sequence motif of DxExNPGP, and which induce ribosome skipping during protein translation in cells, thereby inhibiting ribosomes from making peptide bonds.
[0093] At this time, the self-cleavage sequence may be a 2A peptide derived from porcine teschovirus-1 (PTV1) (P2A), Thosea asigna virus (TaV) (T2A), equine rhinitis A virus (ERAV) (E2A), or foot and mouth disease virus (FMDV) (F2A). Preferably, it may be P2A.
[0094] In one specific example, the P2A may also have an amino acid sequence of SEQ ID NO: 24. In addition, the nucleotide encoding the P2A may consist of a nucleic acid sequence of SEQ ID NO: 11.
[0095] In one specific example, the nucleotides encoding the P2A can comprise a nucleic acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% identity to SEQ ID NO: 11.
[0096] In one specific example, the T2A may have an amino acid sequence of SEQ ID NO: 39, the E2A may have an amino acid sequence of SEQ ID NO: 40, and the F2A may have an amino acid sequence of SEQ ID NO: 41.
[0097] As used herein, the term "IRES (internal ribosome entry site)" refers to an internal ribosome entry site or ribosome binding site that forms a loop structure on mRNA and initiates translation of the mRNA. If such an IRES exists, a gene located downstream of the IRES can be expressed. In one specific example, the gene construct may include nucleotides encoding a self-cleavage sequence between nucleotides encoding a decoy peptide and nucleotides encoding a CCN5 protein or a fragment thereof.
[0098] Specifically, the genetic construct may comprise, from the 5'-end to the 3'-end, a nucleotide encoding a decoy peptide, a nucleotide encoding a self-cleavage sequence, and a nucleotide encoding a CCN5 protein or a fragment thereof.
[0099] Cell membrane permeable peptide
[0100] Additionally, the genetic construct may further comprise nucleotides encoding a cell membrane-penetrating peptide. In this case, the cell membrane-penetrating peptide may be additionally linked to the N-terminus and / or the C-terminus.
[0101] As used herein, the term "cell-penetrating peptide (CPP)" refers to a short peptide that promotes cellular uptake and absorption, and is capable of passing through the phospholipid bilayer cell membrane itself. The CPP can deliver a delivery agent containing the CPP into cells through direct penetration, endocytosis, or reverse micelle formation.
[0102] In order to transport the decoy peptide of the present invention into cardiomyocytes, the decoy peptide must contain a cell membrane-penetrating peptide. As used herein, the term "cell membrane-penetrating peptide" refers to a peptide essential for transporting a specific peptide into cells, and typically consists of a sequence of 10-50 amino acids or more.
[0103] At this time, the cell membrane-penetrating peptide may be selected from the group consisting of a Tat-derived peptide, an arginine-rich peptide, a transportan, and an amphipathic peptide carrier. In addition, the cell membrane-penetrating peptide may be various antennapedia-based peptides having cell membrane-penetrating properties, including retroinverso and D-isomer peptides, or variants thereof (Brugidou, J.et.al., BiochemBiophys Res Commun., 214(2):685-93 (1995); Derossi, D.et.al., TrendsCellBiol., 8:84-87 (1998)). Preferably, the cell membrane-penetrating peptide is a TAT peptide (Tat-derived peptide) or a variant thereof.
[0104] As used herein, the term "TAT peptide" refers to approximately 86 amino acids derived from human immunodeficiency virus (HIV), and is also called Tat-derived peptide, TAT. TAT peptides have a main protein domain of cysteine-rich, basic, and integrin-binding portions. At this time, the TAT peptide may have at least one amino acid substituted to enhance cell penetration ability. In this specification, TAT peptides or variants thereof are also collectively referred to as "TAT peptides." For information regarding variants of TAT peptides (Tat-derived peptides), please refer to "A novel cell-penetrating peptide to facilitate intercellular transport of fused proteins., Shen Y. et al., J Control Release., Aug 28, 2014."
[0105] In one specific example, the TAT peptide of the present invention may have an amino acid sequence of SEQ ID NO: 16 or 38. In addition, the TAT peptide may comprise an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% identity with SEQ ID NO: 16 or 38.
[0106] As used herein, the term "TAT peptide variant" refers to a form in which a portion of an amino acid of a full-length TAT peptide or a fragment thereof is substituted. That is, the TAT peptide may have an amino acid sequence different from that of the wild-type TAT peptide or a fragment thereof. However, the TAT peptide variant may have an activity equivalent to or similar to that of the wild-type TAT peptide.
[0107] Specifically, the variant of the TAT peptide may be one in which some of the amino acids of the TAT peptide are substituted. As a specific example of the TAT peptide variant by amino acid substitution, at least one of the 2nd, 4th, 5th, 6th, 9th, and 11th amino acids in the amino acid sequence of SEQ ID NO: 38 may be substituted. In one specific example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids may be substituted as long as activity is maintained. In another specific example, 1 to 6 amino acids may be substituted. In another specific example, the variant of the TAT peptide may be one in which the 2nd, 4th, 5th, 6th, 9th, and 11th amino acids in the amino acid sequence of SEQ ID NO: 38 are substituted.
[0108] At this time, the "other amino acid" introduced by the above substitution may be any one selected from the group consisting of alanine (Ala, A), arginine (Arg, R), asparagine (Asn, N), aspartic acid (Asp, D), cysteine (Cys, C), glutamic acid (Glu, E), glutamine (Gln, Q), histidine (His, H), isoleucine (Ile, I), leucine (Leu, L), lysine (Lys, K), methionine (Met, M), phenylalanine (Phe, F), glycine (Gly, G), proline (Pro, P), serine (Ser, S), threonine (Thr, T), tryptophan (Trp, W), tyrosine (Tyr, Y), and valine (Val, V). However, in the amino acid substitution of the above mutant, the 2nd amino acid in the amino acid sequence of SEQ ID NO: 38 cannot be substituted with glycine (G), the 4th and 5th cannot be substituted with lysine (K), and the 6th, 9th, and 11th cannot be substituted with arginine (R).
[0109] In one specific example, in the amino acid sequence of SEQ ID NO: 38, the second position may be substituted with an amino acid other than glycine (G); the fourth and fifth positions may be substituted with an amino acid other than lysine (K); and the sixth, ninth, and eleventh positions may be substituted with an amino acid other than arginine (R).
[0110] In one specific example, the second glycine (G) in the amino acid sequence of SEQ ID NO: 38 may be substituted with alanine (A). The fourth and fifth lysines (K) in the amino acid sequence of SEQ ID NO: 38 may be substituted with alanine (A). The sixth, ninth, and eleventh arginines (R) in the amino acid sequence of SEQ ID NO: 38 may be substituted with alanine (A).
[0111] Specifically, the variant of the TAT peptide may have at least one substitution selected from the group consisting of G2A, K4A, K5A, R6A, R9A, and R11A in the amino acid sequence of SEQ ID NO: 38.
[0112] Specifically, the variant of the TAT peptide may have amino acid substitutions at two, three, four, five or six positions selected from among G2A, K4A, K5A, R6A, R9A and R11A in the amino acid sequence of SEQ ID NO: 38. Furthermore, the variant may have mutations of G2A, K4A, K5A, R6A, R9A and R11A in the amino acid sequence of SEQ ID NO: 38.
[0113] Specifically, the variant of the TAT peptide may comprise the amino acid sequence of SEQ ID NO: 16.
[0114] Additionally, the variant of the TAT peptide may have a repeating amino acid sequence of SEQ ID NO: 16. The amino acid sequence of SEQ ID NO: 16 may be repeated 1 to 5 times. Specifically, it may be repeated 1 to 4 times, or 1 to 3 times, and preferably 3 times. The repeating may be repeated by direct connection without a peptide linker.
[0115] In one specific example, the variant of the TAT peptide may have the amino acid sequence of SEQ ID NO: 15.
[0116] In addition, the nucleotide sequence encoding the TAT peptide of the present invention or a variant thereof may include a nucleic acid sequence of SEQ ID NO: 2. In addition, the nucleotide sequence encoding the TAT peptide may include a nucleic acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% identity with SEQ ID NO: 2.
[0117] In one specific example, the genetic construct may comprise nucleotides encoding a membrane-penetrating peptide and nucleotides encoding a decoy peptide in a 5'- to 3'-terminal direction. Furthermore, the genetic construct may comprise nucleotides encoding a decoy peptide and nucleotides encoding a membrane-penetrating peptide in a 5'- to 3'-terminal direction.
[0118] Additionally, the above-described cell membrane permeable peptides may be included in multiple numbers within the gene construct, and may include one, two, or three. Additionally, when multiple cell membrane permeable peptides are included, they may be located at the 5'-end and / or 3'-end of the nucleotide encoding the decoy peptide.
[0119] Specific examples of genetic construct structures
[0120] In one specific example, the genetic construct may comprise, from the 5'-end to the 3'-end, a nucleotide encoding a cell membrane permeability peptide, a nucleotide encoding a decoy peptide, and a nucleotide encoding a CCN5 protein or a fragment thereof.
[0121] In one specific example, the genetic construct may comprise, from the 5'-end to the 3'-end, a nucleotide encoding a cell membrane permeability peptide, a nucleotide encoding a decoy peptide, a nucleotide encoding a self-cleavage sequence, and a nucleotide encoding a CCN5 protein or a fragment thereof.
[0122] In one embodiment, when SP-TATm3-SE (Decoy Peptide)-P2A-CCN5, which is a specific example of the gene construct, is expressed in a cell, it was confirmed that the decoy peptide and CCN5 protein can be secreted extracellularly, respectively. In addition, it was confirmed that the secreted decoy peptide and CCN5 can re-enter the cell. Therefore, it was confirmed that when the SP-TATm3-SE (Decoy Peptide)-P2A-CCN5 is expressed in an organism, the decoy peptide and CCN5 can be secreted from the cell in which they are produced and absorbed into surrounding cells and tissues.
[0123] The genetic construct may additionally include nucleotides encoding the decoy peptide. That is, the genetic construct may include multiple nucleotides encoding the decoy peptide. For example, the genetic construct may include nucleotides encoding the decoy peptide 1 to 7 times, 1 to 6 times, 2 to 6 times, 2 to 5 times, 1 to 3 times, or 2 to 3 times.
[0124] In one specific example, when a genetic construct includes nucleotides encoding decoy peptides in duplicate, each decoy peptide may be sequentially connected by a linker. In this case, the linker may be a peptide linker.
[0125] In one specific example, the genetic construct may be composed of the following structural formula (II):
[0126] [ SP1 - X - Y - ((L1)p - Y)n- (L2)q - Z ]m - SP2 - T (II)
[0127] At this time, in the above structural formula (II),
[0128] The above X is a nucleotide encoding a cell membrane permeable peptide,
[0129] The above Y is a nucleotide encoding a decoy peptide,
[0130] The above SP1 and SP2 are nucleotides encoding the signal sequence,
[0131] The above L1 and L2 are peptide linkers,
[0132] The above Z is a nucleotide encoding a cleavage sequence,
[0133] The above T is a nucleotide encoding the CCN5 protein or a fragment thereof,
[0134] The above n is an integer from 0 to 3,
[0135] The above m is an integer of any one of 1 to 3,
[0136] The above p and q are 0 or 1, respectively.
[0137] The above cell membrane permeable peptide, decoy peptide, CCN5 protein or fragment thereof is as described above.
[0138] The above signal sequence refers to a signal peptide (SP), and can be placed in front of the sequence encoding the peptide for exposing the decoy peptide and CCN5 protein to the outside of the cell membrane, i.e., for extracellular secretion.
[0139] In one specific example, the signal peptide (SP1) may be composed of an amino acid sequence represented by SEQ ID NO: 14, and the base sequence encoding the same may be a sequence represented by SEQ ID NO: 1. In addition, the signal peptide (SP2) may be composed of an amino acid sequence represented by SEQ ID NO: 25, and the base sequence encoding the same may be a sequence represented by SEQ ID NO: 12.
[0140] The peptide linker may be comprised of 1 to 30 consecutive amino acids, 1 to 20 consecutive amino acids, 1 to 15 consecutive amino acids, or 1 to 10 amino acids. In one specific example, the peptide linker may be comprised of 1 to 8 or 1 to 5 amino acids.
[0141] In one specific example, the linker (Linker, L) may be a glycine linker, a peptide linker consisting of an amino acid sequence of SEQ ID NO: 17, or a peptide linker encoded by a nucleotide sequence of SEQ ID NO: 6.
[0142] In one specific example, when n is 0, m is 1, p is 0, and q is 0, the gene construct may have a structure of SP-XYZ-SP-T in the direction from the 5'-end to the 3'-end. In this case, one specific example of the gene construct may have a structure of SP1-TATm3-SE-P2A-SP2-CCN5.
[0143] In one specific example, when n is 1, m is 1, p is 1, and q is 0, the gene construct may have a structure of SP-XYLYZ-SP-T in the direction from the 5'-end to the 3'-end. In this case, one specific example of the gene construct may have a structure of SP1-TATm3-SE-ggg-SE-P2A-SP2-CCN5.
[0144] In one specific example, when n is 2, m is 1, p is 1, and q is 0, the gene construct may have a structure of SP-XYLYLYZ-SP-T in the direction from the 5'-end to the 3'-end. In this case, one specific example of the gene construct may have a structure of SP1-TATm3-SE-ggg-SE-ggg-SE-P2A-SP2-CCN5.
[0145] In one specific example, when n is 1, m is 2, p is 1, and q is 0, the gene construct may have a structure of SP-XYLYZ-SP-XYLYZ-SP-T in the direction from the 5'-end to the 3'-end. At this time, one specific example of the gene construct may have a structure of SP1-TATm3-SE-ggg-SE-P2A-SP1-TATm3-SE-ggg-SE-P2A-SP2-CCN5.
[0146] In one specific example, when n is 0, m is 2, p is 0, and q is 0, the gene construct may have a structure of SP-XYZ-SP-XYZ-SP-T in the direction from the 5'-end to the 3'-end. In this case, one specific example of the gene construct may have a structure of SP1-TATm3-SE-P2A-SP1-TATm3-SE-P2A-SP2-CCN5.
[0147] In one specific example, when n is 2, m is 2, p is 1, and q is 0, the gene construct may have a structure of SP-XYLYLYZ-SP-XYLYLYZ-SP-T in the direction from the 5'-end to the 3'-end. At this time, one specific example of the gene construct may have a structure of SP1-TATm3-SE-ggg-SE-ggg-SE-P2A-SP1-TATm3-SE-ggg-SE-ggg-SE-P2A-SP2-CCN5.
[0148] Recombinant vector containing a genetic construct
[0149] Another aspect of the present invention provides a recombinant vector comprising the genetic construct.
[0150] The term "recombinant vector" as used herein refers to a recombinant expression vector capable of expressing a target protein in a target host cell, and refers to a genetic construct that includes essential regulatory elements operatively linked to enable expression of a gene insert.
[0151] Additionally, the recombinant expression vector may include a signal sequence for export of the fusion polypeptide to facilitate protein isolation from cell culture media. A specific initiation signal may also be required for efficient translation of the inserted nucleic acid sequence. These signals include the ATG initiation codon and adjacent sequences. In some cases, an exogenous translational control signal, which may include the ATG initiation codon, must be provided. These exogenous translational control signals and initiation codons may come from a variety of natural and synthetic sources. Expression efficiency may be increased by the introduction of appropriate transcriptional or translational enhancing factors.
[0152] The recombinant vector of the present invention is a means for introducing a protein into a cell and expressing the protein, and a known recombinant vector such as a plasmid vector, a cosmid vector, or a bacteriophage vector can be used, and the recombinant vector can be easily produced by a person skilled in the art according to any known method using DNA recombination technology.
[0153] For example, pWE15, M13, Charon4A, and Charon21A can be used as phage vectors or cosmid vectors, and pBR series, pUC series, pBluescriptII series, pGEM series, pTZ series, pCL series, and pET series can be used as plasmid vectors. The recombinant vectors usable in the present invention are not particularly limited, and known expression vectors can be used.
[0154] Methods for introducing the recombinant vector into a host cell can be employed using methods known in the art. For example, but not limited to, transient transfection, microinjection, transduction, cell fusion, calcium phosphate precipitation, liposome-mediated transfection, DEAE dextran-mediated transfection, polybrene-mediated transfection, electroporation, gene gun, or other known methods for introducing nucleic acids into cells can be employed (Wuet et al., J. Bio. Chem., 267:963-967, 1992; Wu and Wu, J. Bio. Chem., 263:14621-14624, 1988).
[0155] Recombinant virus containing a genetic construct
[0156] Another aspect of the present invention provides a recombinant virus comprising the genetic construct.
[0157] The virus may be any one selected from the group consisting of adenovirus, adeno-associated virus (AAV), retrovirus, lentivirus, herpes simplex virus, Anelloviridae, and vaccinia virus. Specifically, the virus may be adeno-associated virus.
[0158] The above adenovirus is widely used as a gene transfer vector due to its medium genome size, ease of manipulation, high titer, wide target cell range, and excellent infectivity. The genome may contain 100 to 200 bp inverted terminal repeats (ITRs), which are cis elements essential for DNA replication and packaging. The genome may further contain the E1 region (E1A and E1B), which encodes proteins involved in viral DNA replication.
[0159] However, among adenovirus vectors, replication-deficient adenoviruses lacking the E1 region can be used. Meanwhile, the E3 region is removed from conventional adenovirus vectors, providing a site for insertion of foreign genes.
[0160] The retroviruses described above are widely used as gene transfer vectors because they can insert their genes into the host genome, carry large amounts of foreign genetic material, and have a wide spectrum of cells they can infect. To construct a retroviral vector, a genetic construct containing the decoy gene and the CCN5 gene is inserted into the retroviral genome in place of the retroviral sequence, resulting in a replication-incompetent virus.
[0161] The above adeno-associated virus (AAV) is suitable as a gene delivery system of the present invention because it can infect non-dividing cells and has the ability to infect various types of cells. The AAV virus can be produced by co-transfecting a plasmid containing a gene construct including SE and CCN5 genes flanked by two AAV terminal repeats and an expression plasmid containing a wild-type AAV coding sequence without a terminal repeat, thereby producing an AAV having the gene construct of the present invention.
[0162] Vectors derived from the above vaccinia virus, lentivirus or herpes simplex virus can also be used to transport the gene for the CCN5 protein and the desired nucleotide sequence to be transported into cells.
[0163] Pharmaceutical composition
[0164] Another aspect of the present invention provides a pharmaceutical composition comprising the genetic construct, the recombinant vector or the recombinant virus as an active ingredient.
[0165] The above pharmaceutical composition may be used for preventing or treating heart disease.
[0166] The above heart disease is a general term for all diseases that occur in the heart due to weakened heart function, etc. The above heart disease is not limited to heart failure, ischemia, arrhythmia, myocardial infarction, congestive heart failure, transplant rejection, abnormal heart contraction, and abnormal Ca 2+ It may be selected from a group consisting of ambassadors. Preferably, it may be heart failure.
[0167] The pharmaceutically acceptable carrier included in the pharmaceutical composition of the present invention, when in the form of a preparation, may include at least one selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil, but is not limited thereto.
[0168] The formulation of the above pharmaceutical composition may vary depending on the method of use, but it may be prepared as an injection.
[0169] It is recommended that the dosage of the pharmaceutical composition of the present invention be determined by considering the patient's age, sex, condition, absorption rate of the active ingredient in the body, inactivation rate, and concomitantly administered drug. If the pharmaceutical composition is a virus, it is 1.0×10 per day for adults. 3 1.0×10 20 It can be administered in the amount of viral genome. Specifically, the dosage of the pharmaceutical composition of the present invention is 1.0×10 per day for adults. 3 1.0×10 20 , 1.0×10 8 1.0×10 16 , 1.0×10 12 1.0×10 15 or 1.0×10 13 1.0×10 14 It can be administered in the amount of .
[0170] Pharmaceutical composition for combination administration
[0171] Another aspect of the present invention provides a pharmaceutical composition for preventing or treating heart failure, comprising the decoy peptide and CCN5 protein as active ingredients.
[0172] The pharmaceutical composition of the present invention is administered parenterally, and parenteral administration includes intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, inhalation administration using the nasal cavity, and direct injection into tissue.
[0173] As used herein, the term "acceptable carrier" includes any or all of the following materials suitable for a particular dosage: solvents, diluents, liquid carriers, dispersants, suspending aids, surfactants, isotonic agents, thickeners, emulsifiers, preservatives, solid binders, lubricants, or the like. Examples of pharmaceutical compositions of pharmaceutically acceptable carriers include, but are not limited to: sugars such as glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter, suppository wax, peanut butter, cottonseed oil, safflower oil, sesame oil, olive oil, and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; Buffers such as magnesium hydroxide, aluminum hydroxide; alginic acid; distilled water to remove pyrogens; isotonic saline; Ringer's solution; ethyl alcohol and phosphate buffered water and sodium lauryl sulfate and magnesium stearate, and coloring agents, release agents, coating agents, sweeteners, flavoring agents and fragrances, antioxidants, etc. may be included at the discretion of the compound manufacturer.
[0174] Uses of pharmaceutical compositions
[0175] Another aspect of the present invention provides a method for preventing or treating heart disease, comprising administering the pharmaceutical composition to a subject.
[0176] As described above, the pharmaceutical composition may be a pharmaceutical composition for preventing or treating heart disease, containing as an active ingredient a gene construct comprising a nucleotide encoding a decoy peptide that inhibits protein phosphatase 1 (PP1)-mediated dephosphorylation of phospholamban (PLB); and a nucleotide encoding a CCN5 protein or a fragment thereof.
[0177] In addition, the pharmaceutical composition may be a pharmaceutical composition for preventing or treating heart disease containing a recombinant vector including the gene construct as an active ingredient.
[0178] In addition, the pharmaceutical composition may be a pharmaceutical composition for preventing or treating heart disease containing a recombinant virus including the gene construct as an active ingredient.
[0179] The subject may be a mammal, preferably a human. Specifically, the subject may be a human or non-human mammal that may be or is suffering from a heart disease.
[0180] Another aspect of the present invention provides a pharmaceutical composition for preventing or treating heart disease, comprising a recombinant virus comprising a genetic construct comprising nucleotides encoding a decoy peptide; and a recombinant virus comprising a genetic construct comprising nucleotides encoding a CCN5 protein or a fragment thereof.
[0181] The above decoy peptide is the same as described above in the above gene construct. The above CCN5 protein or fragment thereof is the same as described above in the above gene construct.
[0182] Another aspect of the present invention provides a use of the pharmaceutical composition for preventing or treating heart disease.
[0183] Another aspect of the present invention provides a use of the pharmaceutical composition for preparing a medicament for the prevention or treatment of heart disease.
[0184] Hereinafter, the present invention will be described in detail through manufacturing examples and examples. However, the following manufacturing examples and examples are only intended to illustrate the present invention, and the present invention is not limited to the following manufacturing examples and examples.
[0185] Manufacturing Example 1. Manufacturing of Gene Construct
[0186] In order to express the CCN5 protein and SE peptide (decoy peptide) separately and simultaneously, the gene constructs pUC-scCMV-SPTATm3-SE-P2A-CCN5, pUC-scCMV-SPTATm3-SESE-P2A-CCN5, pUC-scCMV-SPTATm3-SESESE-P2A-CCN5, pUC-scCMV-SPTATm3-SESESE-P2A-CCN5, and pUC-scCMV-SPTATm3-SESESE-dNP2-SESESE-CCN5 were prepared as shown in FIGS. 1A to 1D.
[0187] As shown in Table 1 below, it was produced in a form including a nucleotide sequence encoding a signal peptide (SP) for secreting the peptide outside of the cell, a cell permeable peptide (CPP) TATm3, and a nucleotide sequence encoding an SE peptide (decoy peptide). Next, a self-cleavage sequence P2A was connected, followed by a CCN5 protein. The CPP and SE peptide, the repeated SE peptides, and the SE peptide and the P2A sequence were connected with a glycine linker (ggg).
[0188] Nucleotide sequenceSignal peptide 1(SEQ ID NO: 1)ATGTGGTGGCGCCTTTGGTGGCTCCTTTTGTTGCTGTTGTTGTTGTGGCCTATGGTGTGGGCCAAGCTGTATm3(CPP)(SEQ ID NO: 2)TATGCAAGAGCCGCTGCAAGACAGGCCAGAGCATATGCGAGGGCAGCTGCTAGACAGGCTAGAGCTTATGCTAGAGCAGCTGCCAGGCAGGCTAGAGCTGlycine X3 linker 1(SEQ ID NO: 6)GGTGGAGGASE(Decoy peptide)(SEQ ID NO: 7)AGAGCCGAGACCATCGAAATGCCACAAGlycine X3 linker 2(SEQ ID NO: 8)GGTGGCGGASE(Decoy peptide)(SEQ ID NO: 9)CGGGCCGAGACAATAGAAATGCCTCAGGlycine X3 linker 3(SEQ ID NO: 10)GGAGGAGGAP2A sequence (SEQ ID NO: 11)GGAAGCGGCGCTACTAACTTCTCCCTCCTTAAACAAGCCGGAGACGTGGAAGAGAATCCAGGTCCCSignal peptide 2 (SEQ ID NO: 12)ATGCGTGGTACTCCTAAAACCCATCTGCTGGCTTTTTCTCTGCTGTGTCTGCTGAGCAAAGTTCGTACTCCN5 w / o signal peptide (SEQ ID NO:13)CAGCTGTGGCCCGACCCCGTGTACTTGTCCATGGCCACCACCGCGTTGTCCTCTGGGTGTACCTCTGGTTCTGGACGGTTGCGGCTGTTGTCGTGTTTGCGCCCGTCGTCTGGGCGAACCTTGTGATCAGCTGCACGTTTGCGACGCTTCCCAGGGTCTGGTTTGCCAG CCTGGTGCTGGTCCTGGTGTGTCGTGGTGCACTGTGCCTGCTGGCTGAAGACGACTCTTCTTGTGAAGTAAACGGTCGTCTGTACCGTGAAGGTGAGACCTTCCAGCCACATTGCTCTATTCGCTGCCGCTGCGAAGATGGGCGGCTTTACTTGTGTTCCTCTGTGCTCCGAAG ACGTTCGTCTGCCGTCTTGGGATTGTCCTCATCCGCGTCGTGTTGAAGTGCTGGGCAAATGCTGCCCGGAATGGGTTTGCGGTCAAGGTGGTGGTCTGGGTACTCAACCGCTGCCGGCTCAGGGTCCACAATTCTCTGGCCTGGTTAGCAGCCTGCCGCCTGGTGTTCCTTG TCCAGAATGGAGCACGGCTTGGGGCCCTTGTTCTACCACTTGGCGGCCTGGGTATGGCTACCCGTGTTTCCAACCAGAACCGTTTTTGTCGTCTGGAAACCCAGCGTCGTCTGTGTCTGAGCCGTCCGTGTCCGCCATCTCGTGTGTCGTTCCCCACAGAACTCCGCTTTCTGA
[0189] At this time, the P2A sequence was composed of a base sequence encoding 22 amino acids as a self-cleavage site derived from porcine teschovirus-1, and CCN5 used a sequence obtained by codon-optimizing the cDNA of the human CCN5 protein.
[0190] The amino acid sequence expressed using the above gene construct is as shown in Table 2 below.
[0191] Amino acid sequenceSignal peptide 1(SEQ ID NO: 14)MWWRLWWLLLLLLLLWPMVWAKLTATm3(CPP)(SEQ ID NO: 15)YARAAARQARAYARAAARQARAYARAAARQARAGlycine X3 linker 1(SEQ ID NO: 17)GGGSE1(Decoy peptide)(SEQ ID NO: 18)RAETIEMPQGlycine X3 linker 2(SEQ ID NO: 17)GGGSE1(Decoy peptide)(SEQ ID NO: 18)RAETIEMPQGlycine X3 linker 3(SEQ ID NO: 17)GGGP2A sequence(SEQ ID NO: 24)GSGATNFSLLKQAGDVEENPGPSignal peptide 2(SEQ ID NO: 25)MRGTPKTHLLAFSLLCLLSKVRTCCN5 w / o signal peptide(SEQ ID NO: 26)QLCPTPCTCPWPPPRCPLGVPLVLDGCGCCRVCARRLGEPCDQLHVCDASQGLVCQPGAGPGRGGALCLAEDDSSCEVNGRLYREGETFQPHCSIRRCRCEDGGFTCVPLCS EDVRLPSWDCPHPRRVEVLGKCCPEWVCGQGGGLGTQPLPAQGPQFSGLVSSLPPGVPCPEWSTAWGPCSTTCGLGMATRVSNQNRFCRLETQRRLCLSRPCPPSRGRSPQNSAF
[0192] Manufacturing Example 2. Production of AAV vector
[0193] AAV vectors were constructed for the constructs BTG001 (expressing CCN5 alone), BTG010 (expressing CPP and decoy peptide (TATm3-SESE)), and BTG011 (expressing TATm3-SESE and CCN5). The three types of AAV viruses, BTG001, BTG010, and BTG011, are as follows:
[0194] BTG001 is an adeno-associated virus (ADEV) that packages a construct that exclusively expresses the CCN5 protein via the CMV promoter. During gene transfer, BTG001 expresses the CCN5 protein in target tissues according to the tropism of AAV. The CCN5 protein is secreted from infected cells into the extracellular matrix and acts.
[0195] BTG010 is an adeno-associated virus (ADEV) that packages a construct that exclusively expresses the SPTATm3-SESE peptide via the CMV promoter. During gene transfer, BTG010 expresses the SPTATm3-SESE peptide in target tissues according to the tropism of AAV, and SPTATm3 is secreted from infected cells into the extracellular matrix and acts.
[0196] BTG011 is an adeno-associated virus (ADEV) that packages a construct that simultaneously expresses the SPTATm3-SESE peptide and the CCN5 protein, driven by the CMV promoter. BTG011 expresses both the peptide and the protein, respectively, due to the self-cleavage sequence between SPTATm3-SESE and CCN5, and acts on target tissues according to AAV tropism. Furthermore, SPTATm3-SESE and CCN5 are secreted from infected cells into the extracellular matrix, where they act.
[0197] Specifically, the ITR-CMV-SPTATm3-SESE-bGH poly(A)-ITR, ITR-CMV-CCN5-bGH poly(A)-ITR, and ITR-CMV-SPTATm3-SESE-P2A-CCN5-bGH poly(A)-ITR gene constructs were cloned into the pUC57-kan vector, respectively, to complete the pUC-scCMV-CCN5(BTG001), pUC-scCMV-SPTATm3-SESE(BTG010), and pUC-scCMV-SPTATm3-SESE-P2A-CCN5(BTG011) recombinant plasmids.
[0198] Among the above recombinant plasmids, the protein produced by BTG011 is divided into the SPTATm3-SESE peptide and the CCN5 protein by self-cleavage between amino acids glycine (21st amino acid) and proline (22nd amino acid) in the P2A region. The SPTATm3-SESE peptide and the CCN5 protein are transported into the endoplasmic reticulum and then secreted outside the cell in a form in which the signal peptide is cleaved, thereby allowing them to perform their original function.
[0199] To produce self-complementary adeno-associated virus (AAV, serotype 9), 293T cells were used to produce pUC-scCMV-CCN5 (BTG001), pUC-scCMV-SPTATm3-SESE (BTG010), and pUC-scCMV-SPTATm3-SESE-P2A-CCN5 (BTG011), respectively, together with the Rep-Cap plasmid and helper plasmid required for virus packaging, to produce BTG001, BTG010, and BTG011.
[0200] AAV particles in cell culture media were collected, precipitated with ammonium sulfate, and purified by ultracentrifugation using an iodixanol gradient. AAV particles were concentrated through multiple dilution and concentration steps, with centrifugation exchanging iodixanol for lactate Ringer's solution. AAV concentration was quantified using quantitative RT-PCR and SDS-PAGE.
[0201] Example 1. Transfection and Conditioned Media Treatment
[0202] 3 μg of the plasmid prepared in Manufacturing Example 1 was mixed with lipofectamine2000 (Invitrogen) at a ratio of 1:2 (w / v) in AD293 cells, incubated for 30 minutes, and treated the cells. The medium was changed after 4 hours, and the medium was harvested after 24 hours, and the medium was treated to each experimental group.
[0203] Example 2. Western blot
[0204] Cells or cardiac tissues were homogenized in a minimal volume of 50 mM Tris-HCl, pH 7.4, supplemented with a Broad Spectrum Protease Inhibitor Cocktail (Calbiochem). Proteins were separated by SDS-PAGE and transferred to polyvinylidene fluoride membranes (Schleicher & Schuell). After blocking with 5% (w / v) skim milk for 1 h and washing with TBST, the membranes were reacted with the indicated antibodies. The antibodies used in the present invention are as follows: CCN5 antibody (Sigma Aldrich), HA (Roche), α-SMA (Sigma Aldrich), p21 (Invitrogen), myc (Santa Cruz), PCNA (abcam), phospho-eNOS (ser1177) (Cell signaling), eNOS (Cell signaling), GAPDH antibody (Sigma-Aldrich). The membrane was then reacted with HRP-conjugated secondary antibody (Jackson ImmunoResearch, WestGrove, PA, USA) and developed using a chemiluminescent substrate (ECL western solution, DoGen, Korea). Images were taken and quantified using LAS software.
[0205] Example 3. Quantitative RT-PCR
[0206] Real-time PCR was performed using the QuantiTect SYRB Green real-time PCR Kit (Qiagen Ltd) to analyze transcription levels. RNA was isolated from heart tissue using Trizol (gibco BRL), and cDNA was synthesized from it. Various quantitative real-time PCR conditions were 37 cycles: 94°C for 10 s, 57°C for 15 s, and 72°C for 5 s. Information on the primers used in the experiments is shown in Table 3 below.
[0207] Forward Reverse Human α-SMA 5'-GCCCAGCCAAGCACTGTCAGGA-3' (SEQ ID NO: 29) 5'-TCCCACCATCACCCCCTGATGTC-3' (SEQ ID NO: 30) Human Fibronectin 5'-CTGGCCGAAAATACATTGTAAA-3' (SEQ ID NO: 31) 5'-CCACAGTCGGGTCAGGAG-3' (SEQ ID NO: 32) Human Vimentin 5'-GAGAACTTTGCCGTTGAAGC-3' (SEQ ID NO: 33) 5'-CGTGATGCTGAGAAGTTTCG-3' (SEQ ID NO: 34) 18s rRNA 5'-TAACGAACGAGACTCTGGCAT-3' (SEQ ID NO: 36) 5'-CGGACATCTAAGGGCATCACAG-3' (SEQ ID NO: 37)
[0208] Data are expressed as mean ± SD. Group means were compared using Student's test or one-way ANOVA with Bonferroni's post hoc test (Statview, V5.0, SAS). P < 0.05 was considered statistically significant.
[0209] Example 4. Confirmation of gene construct expression
[0210] Example 4.1. Confirmation of extracellular secretion of SE peptide and CCN5 by SPTATm3.
[0211] AD293 cells were transfected with 3 μg of DNA plasmid constructs of CCN5, SE-CCN5, SPTATm3-SE-CCN5, and dNP2-SE-CCN5, and 24 h later, the expression of SE peptide and CCN5 protein in intracellular protein lysates and media was confirmed by Western blotting. The expression of SE peptide was confirmed using HA and myc tags.
[0212] At this time, the structures of CCN5, SE-CCN5, SPTATm3-SE-CCN5, and dNP2-SE-CCN5 are pds-hCCN5, pcDNA3.1 (+)-SEgggSEgggSE-HA-P2A-SEgggSEgggSE-myc-P2A-CCN5, respectively, in that order. They were pcDNA3.1(+)-SPTATmX3-SEgggSEgggSE-HA-P2A-SPTATmX3-SEgggSEgggSE-myc-P2A-CCN5 and pcDNA3.1(+)-dNP2-SEgggSEgggSE-HA-P2A-dNP2-SEgggSEgggSE-myc-P2A-CCN5.
[0213] As a result, as shown in FIGS. 2 and 3, it was confirmed that the construct using SP-TATm3 as a CPP secreted SE peptide and CCN5 to the outside of cells better than the construct using dNP2 as a CPP or the construct not including CPP.
[0214] Example 4.2. Confirmation of CCN5 expression level according to SE peptide repeats.
[0215] AD293 cells were transfected with 3 μg of DNA plasmid constructs of SPTATm3-SE-CCN5, SPTATm3-SESE-CCN5, SPTATm3-SESESE-CCN5, and SPTATm3-dNP2SE-CCN5, and the expression of SE peptides and CCN5 protein in the media was confirmed by Western blotting 24 h later. The expression of SE peptides was confirmed using HA and myc tags.
[0216] At this time, the structures of the SPTATm3-SE-CCN5, SPTATm3-SESE-CCN5, SPTATm3-SESESE-CCN5 and SPTATm3-dNP2SE-CCN5 constructs were SPTATmX3-SE-HA-P2A-CCN5, SPTATmX3-SEgggSE-HA-P2A-CCN5, SPTATmX3-SEgggSEgggSE-HA-P2A-CCN5 and SPTATmX3-SEgggSEgggSE-HA-dNP2-SEgggSEgggSE-myc-P2A-CCN5, respectively.
[0217] As a result, as shown in Fig. 4, the construct using only SPTATm3 as a CPP showed higher expression of extracellular SE peptide and CCN5 than the construct using both SPTATm3 and dNP2 as CPP, and it was confirmed that all constructs containing SE peptide once to three times showed higher expression levels of SE peptide and CCN5.
[0218] Example 4.3. Confirmation of introduction of SE peptide and CCN5 into various types of cells.
[0219] AD293 cells were transfected with 3 μg of SE-CCN5, SESE-CCN5, SESESE-CCN5, and CCN5 DNA plasmid constructs, and the medium was collected 24 h later. The obtained medium was applied to smooth muscle cells (SMCs), endothelial cells (ECs), and normal human ventricular cardiac fibroblasts (NHCF-v), respectively.
[0220] At this time, the structures of SE-CCN5, SESE-CCN5, SESESE-CCN5 and CCN5 constructs were SPTATmX3-SE-HA-P2A-CCN5, SPTATmX3-SEgggSE-HA-P2A-CCN5, SPTATmX3-SEgggSEgggSE-HA-P2A-CCN5 and CCN5 alone, respectively.
[0221] Subsequently, Western blot was performed to confirm the presence of SE peptide and CCN5 protein in each cell. In other words, it was confirmed whether SE peptide and CCN5 protein were properly introduced into each cell.
[0222] As a result, as shown in FIGS. 5 and 6, respectively, it was confirmed that the expression levels of SE peptide and CCN5 were high in the construct in which SE peptide was repeated twice and that it was well introduced into both SMCs and ECs cells.
[0223] Meanwhile, in the case of NHCF-v, after treatment with TGF beta (TGFb) for 48 hours, each experimental group construct was treated in the medium for 48 hours, and the protein expression of a-SMA, p21, and GAPDH was confirmed. As a result, as shown in Fig. 7, it was confirmed that a-SMA and p21, which were increased by TGFb, were reduced by SE peptide and CCN5.
[0224] In addition, the mRNA expression of a-SMA, vimentin, and fibronectin in NHCF-v was confirmed through qRT-PCR. As a result, as shown in Figures 8 to 10 , similar to the Western blot results, it was confirmed that a-SMA, vimentin, and fibronectin, which were increased by TGFb, were reduced by SE peptide and CCN5.
[0225] Example 4.4. Confirmation of expression and extracellular secretion patterns of SE peptide and CCN5 according to structural changes in the gene construct.
[0226] The expression and extracellular secretion patterns of SE peptide and CCN5 were confirmed according to the structural switching of SE peptide and CCN5 and the location of the cell membrane permeable peptide (CPP) of SE peptide.
[0227] Specifically, AD293 cells were transfected with 3 μg of each of the following DNA plasmid constructs: i) CCN5 single expression, ii) N'(N-terminal)-CPP-SE and P2A-CCN5 multiple expression, iii) N'-CCN5-P2A and CPP-SE multiple expression, and iv) SE-CPP-C'(C-terminal) and P2A-CCN5 multiple expression. 24 h after transfection, the expression of SE peptide and CCN5 protein in the intracellular protein lysate and media was confirmed by Western blotting.
[0228] At this time, the structures of the above i), ii), iii) and iv) constructs were CCN5 alone, SP-TATm3-SESE-P2A-CCN5, CCN5-P2A-SP-TATm3-SESE and SP-SESE-TATm3-P2A-CCN5, respectively, in that order.
[0229] As a result, when construct ii) SP-TATm3-SESE-P2A-CCN5 (BTG011) was compared with iii) CCN5-P2A-SP-TATm3-SESE, it was confirmed that the expression of SE peptide and CCN5 within the cell was significantly reduced due to the structural switching of SE peptide and CCN5 (Fig. 11b). In addition, it was confirmed that the amounts of SE peptide and CCN5 secreted into the medium were also significantly reduced (Fig. 11c).
[0230] In addition, when construct ii) SP-TATm3-SESE-P2A-CCN5 (BTG011) was compared with iv) SP-SESE-TATm3-P2A-CCN5, the expression of intracellular SE peptide and CCN5 was slightly increased (Fig. 11b), but the amount of SE peptide and CCN5 secreted into the medium did not increase (Fig. 11c).
[0231] Meanwhile, in the case of SE peptide, construct iv) SP-SESE-TATm3-P2A-CCN5 showed increased intracellular peptide expression (Fig. 11b), but secretion into the medium was further reduced (Fig. 11c). It was confirmed that the structural location of CPP affects the expression and secretion of SE peptide and CCN5.
[0232] Example 5. Confirmation of the therapeutic effect of AngII in a heart failure mouse model.
[0233] Example 5.1. Creation of AngII heart failure mouse animal model
[0234] To create an angiotensin II (AngII) heart failure mouse animal model, C57BL / 6 mice were administered 3 mg / kg / day of angiotensin II (AngII) via an osmotic pump for 2 weeks.
[0235] Example 5.2. Confirmation of the therapeutic effect of gene construct injection on heart failure.
[0236] Six weeks after the production of the mice in Example 5.1 above, three types of AAV viruses, BTG001, BTG010, and BTG011, were injected at a concentration of 1×10 11 vg, 5×10 10 vg, 1×10 10 vg or 5×10 9 Each dose was injected as much as vg, and after 6 weeks, the cardiac contractility (fractional shortening) was confirmed through echocardiography.
[0237] As a result, as shown in Fig. 12, it was confirmed that the cardiac contractility increased compared to the control group (AngII) in all mice injected with three types of AAV viruses, BTG001, BTG010, and BTG011. In particular, in mice injected with BTG011, the increase in cardiac contractility was remarkable at all doses, and it was confirmed that the cardiac contractility was restored to the level of normal mice. These results imply that the genetic construct that simultaneously expresses the SPTATm3-SESE peptide and the CCN5 protein effectively treats cardiac disease.
[0238] Additionally, the degree of cardiac fibrosis was confirmed through Trichrome staining 6 weeks after gene construct injection, and the degree of fibrosis area among the entire tissue area was quantified using Imagescope.
[0239] As a result, as shown in Figures 13 and 14, it was confirmed that the degree of cardiac fibrosis was reduced in all mice injected with three types of AAV viruses, BTG001, BTG010, and BTG011. In particular, the anti-fibrosis effect was confirmed to be the most significant in mice injected with BTG011. These results imply that a genetic construct that simultaneously expresses the SPTATm3-SESE peptide and the CCN5 protein effectively treats cardiac disease.
[0240] Example 6. Confirmation of the therapeutic effect of AngII in a heart failure mouse model.
[0241] Example 6.1. Production of a mouse model of heart failure due to aortic cross-stenosis
[0242] To create an animal model of pressure overload (heart failure) due to transverse aortic constriction (TAC), 8-10 week old C57BL / 6 male mice (weighing 25-30 g) were used in the study.
[0243] Mice were anesthetized by intraperitoneal injection with a solution containing 95 mg / kg ketamine and 5 mg / kg xylazine. Mice were ventilated using an oxygen respirator at a tidal volume of 0.2 and a respiratory rate of 11 breaths / min (Harvard Apparatus). A 2- to 3-mm longitudinal incision was made in the proximal sternum to expose the aortic arch. A 27-gauge needle was placed between the innominate artery and the left common carotid artery, and the transverse aortic arch was ligated. The needle was immediately removed, and the incision was closed.
[0244] Example 6.2. Confirmation of the therapeutic effect of gene construct injection on heart failure.
[0245] Six weeks after the production of the mice in Example 6.1 above, three types of AAV viruses, BTG001, BTG010, and BTG011, were injected at a concentration of 1×10 10 After each injection of vg, the mouse heart weight and body weight were measured 6 weeks later, and the cardiac contractility (fractional shortening) was confirmed through echocardiography.
[0246] As a result, as shown in Figures 15 and 16, it was confirmed that the heart weight / body weight ratio decreased and the cardiac contractility increased compared to the control group (TAC) in all mice injected with the three types of AAV viruses BTG001, BTG010, and BTG011. In particular, it was confirmed that the decrease in the heart weight (HW) / body weight (BW) ratio and the increase in cardiac contractility were significant in mice injected with BTG011. These results imply that a genetic construct that simultaneously expresses the SPTATm3-SESE peptide and the CCN5 protein effectively treats heart disease.
[0247] Additionally, the degree of cardiac fibrosis was confirmed through trichrome staining 6 weeks after gene construct injection, and the degree of fibrosis area among the total tissue area was quantified using Imagescope.
[0248] As a result, as shown in Figures 17 and 18, it was confirmed that the degree of cardiac fibrosis was reduced in all mice injected with three types of AAV viruses, BTG001, BTG010, and BTG011, compared to the control group (TAC). In particular, it was confirmed that the degree of cardiac fibrosis was reduced the most in mice injected with BTG011. These results imply that a genetic construct that simultaneously expresses the SPTATm3-SESE peptide and the CCN5 protein effectively treats cardiac disease.
[0249]
[0250] Sequence list
[0251] Table 4 below lists a sequence list according to one embodiment of the present invention.
[0252] 서열번호이름유형길이서열1Signal peptide 1DNA69bpATGTGGTGGCGCCTTTGGTGGCTCCTTTTGTTGCTGTTGTTGTTGTGGCCTATGGTGTGGGCCAAGCTG2TATm3(CPP)DNA99bpTATGCAAGAGCCGCTGCAAGACAGGCCAGAGCATATGCGAGGGCAGCTGCTAGACAGGCTAGAGCTTATGCTAGAGCAGCTGCCAGGCAGGCTAGAGCT3TAT1DNA33bpTATGCAAGAGCCGCTGCAAGACAGGCCAGAGCA4TAT2DNA33bpTATGCGAGGGCAGCTGCTAGACAGGCTAGAGCT5TAT3DNA33bpTATGCTAGAGCAGCTGCCAGGCAGGCTAGAGCT6Glycine X3 linker 1DNA9bpGGTGGAGGA7SE1(Decoy peptide 1)DNA27bpAGAGCCGAGACCATCGAAATGCCACAA8Glycine X3 linker 2DNA9bpGGTGGCGGA9SE1(Decoy peptide 2)DNA27bpCGGGCCGAGACAATAGAAATGCCTCAG10Glycine X3 linker 3DNA9bpGGAGGAGGA11P2A sequenceDNA66bpGGAAGCGGCGCTACTAACTTCTCCCTCCTTAAACAAGCCGGAGACGTGGAAGAGAATCCAGGTCCC12Signal peptide 2DNA69bpATGCGTGGTACTCCTAAAACCCATCTGCTGGCTTTTTCTCTGCTGTGTCTGCTGAGCAAAGTTCGTACT13CCN5 w / o signalpeptideDNA684bpCAGCTGTGCCCGACCCCGTGTACTTGTCCATGGCCACCACCGCGTTGTCCTCTGGGTGTACCTCTGGTTCTGGACGGTTGCGGCTGTTGTCGTGTTTGCGCCCGTCGTCTGGGCGAACCTTGTGATCAGCTGCACGTTTGCGACGCTTCCCAGGGTCTGGTTTGCCAGCCTGGTGCTGGTCCTGGTGGTCGTGGTGCACTGTGCCTGCTGGCTGAAGACGACTCTTCTTGTGAAGTAAACGGTCGTCTGTACCGTGAAGGTGAGACCTTCCAGCCACATTGCTCTATTCGCTGCCGCTGCGAAGATGGCGGCTTTACTTGTGTTCCTCTGTGCTCCGAAGACGTTCGTCTGCCGTCTTGGGATTGTCCTCATCCGCGTCGTGTTGAAGTGCTGGGCAAATGCTGCCCGGAATGGGTTTGCGGTCAAGGTGGTGGTCTGGGTACTCAACCGCTGCCGGCTCAGGGTCCACAATTCTCTGGCCTGGTTAGCAGCCTGCCGCCTGGTGTTCCTTGTCCAGAATGGAGCACGGCTTGGGGCCCTTGTTCTACCACTTGCGGCCTGGGTATGGCTACCCGTGTTTCCAACCAGAACCGTTTTTGTCGTCTGGAAACCCAGCGTCGTCTGTGTCTGAGCCGTCCGTGTCCGCCATCTCGTGGTCGTTCCCCACAGAACTCCGCTTTCTGA14Signal peptide 1PRT23aaMWWRLWWLLLLLLLLWPMVWAKL15TATm3(CPP)PRT33aaYARAAARQARAYARAAARQARAYARAAARQARA16TATPRT11aaYARAAARQARA17Glycine X3 linkerPRT3aaGGG18SE1(Decoy peptide)PRT9aaRAETIEMPQ19SE2(Decoy peptide)PRT9aaRASEIEMPQ20SE3(Decoy peptide)PRT9aaRADTIEMPQ21SE4(Decoy peptide)PRT8aaAETIEMPQ22SE5(Decoypeptide)PRT7aaRAETIEM23SE6(Decoy peptide)PRT6aaRAETIE24P2A sequencePRT22aaGSGATNFSLLKQAGDVEENPGP25Signal peptide 2PRT23aaMRGTPKTHLLAFSLLCLLSKVRT26CCN5 w / o signal peptidePRT227aaQLCPTPCTCPWPPPRCPLGVPLVLDGCGCCRVCARRLGEPCDQLHVCDASQGLVCQPGAGPGGRGALCLLAEDDSSCEVNGRLYREGETFQPHCSIRCRCEDGGFTCVPLCSEDVRLPSWDCPHPRRVEVLGKCCPEWVCGQGGGLGTQPLPAQGPQFSGLVSSLPPGVPCPEWSTAWGPCSTTCGLGMATRVSNQNRFCRLETQRRLCLSRPCPPSRGRSPQNSAF27PLB_WTPRT52aaMEKVQYLTRSAIRRASTIEMPQQARQKLQNLFINFCLILICLLLICIIVMLL28PLB WT_SEPRT9aaRASTIEMPQ29humanα-SMA_FDNA22bpGCCCAGCCAAGCACTGTCAGGA30humanα-SMA_RDNA23bpTCCCACCATCACCCCCTGATGTC31humanFibronectin_FDNA22bpCTGGCCGAAAATACATTGTAAA32humanFibronectin_RDNA18bpCCACAGTCGGGTCAGGAG33humanVimentin_FDNA20bpGAGAACTTTGCCGTTGAAGC34humanVimentin_RDNA20bpCGTGATGCTGAGAAGTTTCG3518s rRNA_FDNA21bpTAACGAACGAGACTCTGGCAT3618s rRNA_RDNA22bpCGGACATCTAAGGGCATCACAG37Signal peptide 1 w / o start codonPRT22aaWWRLWWLLLLLLLLWPMVWAKL38WTTATPRT11aaYGRKKRRQRRR39T2APRT21aaGSGEGRGSLLTCGDVEENPGP40E2APRT23aaGSGQCTNYALLKLAGDVESNPGP41F2APRT25aaGSGVKQTLNFDLLKLAGDVESNPGP
Claims
1. A genetic construct comprising a nucleotide encoding a decoy peptide that inhibits protein phosphatase 1 (PP1)-mediated dephosphorylation of phospholamban (PLB); and a nucleotide encoding a CCN5 protein or a fragment thereof.
2. In paragraph 1, The above decoy peptide is a genetic construct consisting of a peptide sequence represented by the following structural formula (I): X1-Ala-X2-X3-Ile-Glu-X4 (I) wherein X1 is 0 to 50 amino acid residues, wherein X2 is Ser, Glu or Asp, The above X3 is Thr or Glu, wherein X4 is 0 to 50 amino acid residues, If the above X3 is Thr, then X2 is not Ser.
3. In paragraph 2, A genetic construct wherein the above X1 is 0 to 13 amino acid residues.
4. In paragraph 2, A genetic construct wherein the above X4 is 0 to 33 amino acid residues.
5. In paragraph 3, A genetic construct wherein the above X1 is 0 to 1 amino acid residue.
6. In paragraph 4, A genetic construct wherein the above X4 is 0 to 3 amino acid residues.
7. In paragraph 5, A genetic construct wherein the above X1 is Arg.
8. In paragraph 6, A genetic construct wherein the above X4 is Met, Met-Pro or Met-Pro-Gln.
9. In paragraph 2, A genetic construct wherein the decoy peptide comprises any one amino acid sequence selected from the group consisting of SEQ ID NOs: 18 to 23.
10. In paragraph 1, A genetic construct wherein nucleotides encoding the above decoy peptide and nucleotides encoding the CCN5 protein or a fragment thereof are joined by a self-cleavage sequence.
11. In paragraph 10, A gene construct, wherein the self-cleavage sequence is a nucleotide sequence encoding a 2A peptide derived from porcine teschovirus-1 (PTV1), Thosea asigna virus (TaV), equine rhinitis A virus (ERAV), or foot and mouth disease virus (FMDV).
12. In paragraph 11, A genetic construct wherein the self-cleavage sequence has an amino acid sequence of SEQ ID NO: 24, 39, 40 or 41.
13. In paragraph 1, A genetic construct, wherein a nucleotide encoding a cell membrane-penetrating peptide is additionally linked to the above genetic construct.
14. In paragraph 13, A genetic construct wherein the cell membrane permeable peptide is selected from the group consisting of a Tat-derived peptide, an arginine-rich peptide, a transporter, and an amphipathic peptide carrier.
15. In paragraph 1, A genetic construct, wherein the genetic construct further comprises nucleotides encoding the decoy peptide.
16. In paragraph 1, The above CCN5 protein is a genetic construct having an amino acid sequence of sequence number 26.
17. In paragraph 1, The above genetic construct is a genetic construct composed of the following structural formula (II): [ SP1 - X - Y - ((L1)p - Y)n- (L2)q - Z ]m - SP2 - T (II) At this time, in the above structural formula (II), The above X is a nucleotide encoding a cell membrane permeable peptide, The above Y is a nucleotide encoding a decoy peptide, The above SP1 and SP2 are nucleotides encoding the signal sequence, The above L1 and L2 are peptide linkers, The above Z is a nucleotide encoding a cleavage sequence, The above T is a nucleotide encoding the CCN5 protein or a fragment thereof, The above n is an integer from 0 to 3, The above m is an integer of any one of 1 to 3, The above p and q are 0 or 1, respectively.
18. In paragraph 1, A genetic construct comprising a signal sequence in the above genetic construct.
19. A recombinant vector comprising a gene construct of any one of claims 1 to 18.
20. A recombinant virus comprising a genetic construct of any one of claims 1 to 18.
21. In paragraph 20, A recombinant virus, wherein the virus is any one selected from the group consisting of adenovirus, adeno-associated viruses (AAV), retrovirus, lentivirus, herpes simplex virus, anellovirus, and vaccinia virus.
22. A pharmaceutical composition comprising the genetic construct of paragraph 1, the recombinant vector of paragraph 19, or the recombinant virus of paragraph 20 as an active ingredient.
23. In paragraph 22, The pharmaceutical composition above is for the prevention or treatment of heart disease.
24. In paragraph 23, The above heart diseases include heart failure, ischemia, arrhythmia, myocardial infarction, congestive heart failure, transplant rejection, abnormal heart contraction and abnormal Ca 2+ A pharmaceutical composition selected from the group consisting of ambassadors.
25. A method for preventing or treating heart disease, comprising administering to a subject the pharmaceutical composition of Article 22.
26. Use of a pharmaceutical composition comprising the genetic construct of claim 1, the recombinant vector of claim 19, or the recombinant virus of claim 20 as an active ingredient for preventing or treating heart disease.
27. Use of a pharmaceutical composition comprising the gene construct of claim 1, the recombinant vector of claim 19, or the recombinant virus of claim 20 as an active ingredient for manufacturing a drug for preventing or treating heart disease.
Citation Information
Patent Citations
Decoy peptides for inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban
KR1020140010889A
Modulating phosphatase activity in cardiac cells
US11213534B2
Composition comprising protein phosphatase 1 inhibitory peptide for treating vascular diseases
WO2018080146A2
KR20190038425A
